Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $117,000.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $23.40, for a total value of $117,000.00. Following the completion of the transaction, the chief operating officer now directly owns 246,854 shares in the company, valued at $5,776,383.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Tuesday, June 11th, Jonathan Young sold 2,516 shares of Akero Therapeutics stock. The stock was sold at an average price of $22.64, for a total transaction of $56,962.24.
• On Monday, June 3rd, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $19.29, for a total transaction of $96,450.00.
• On Wednesday, May 1st, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $20.15, for a total transaction of $100,750.00.

Akero Therapeutics Price Performance

AKRO stock traded down $0.78 during midday trading on Tuesday, hitting $22.38. The company’s stock had a trading volume of 430,483 shares, compared to its average volume of 1,092,586. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -7.01 and a beta of -0.28. The company has a 50 day moving average of $21.08 and a two-hundred day moving average of $22.69. The company has a quick ratio of 30.12, a current ratio of 30.12 and a debt-to-equity ratio of 0.04. Akero Therapeutics, Inc. has a 12 month low of $11.25 and a 12 month high of $53.77.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, May 10th. The company reported ($0.90) EPS for the quarter, hitting the consensus estimate of ($0.90). On average, analysts expect that Akero Therapeutics, Inc. will post -3.82 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on AKRO shares. Evercore ISI decreased their target price on Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating on the stock in a report on Wednesday, May 15th. Wolfe Research started coverage on Akero Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a research note on Tuesday, June 11th. UBS Group raised their target price on shares of Akero Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Akero Therapeutics in a research report on Thursday, June 20th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.13.

Institutional Investors Weigh In On Akero Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of AKRO. Teachers Retirement System of The State of Kentucky grew its stake in Akero Therapeutics by 30.0% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 28,521 shares of the company’s stock worth $720,000 after acquiring an additional 6,590 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Akero Therapeutics in the 1st quarter worth $270,000. California State Teachers Retirement System raised its position in shares of Akero Therapeutics by 12.7% in the 1st quarter. California State Teachers Retirement System now owns 54,185 shares of the company’s stock valued at $1,369,000 after purchasing an additional 6,113 shares during the last quarter. Janus Henderson Group PLC raised its stake in Akero Therapeutics by 42.2% in the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock worth $154,589,000 after acquiring an additional 1,815,569 shares during the last quarter. Finally, Redmile Group LLC lifted its holdings in shares of Akero Therapeutics by 67.5% during the first quarter. Redmile Group LLC now owns 1,858,702 shares of the company’s stock worth $46,951,000 after purchasing an additional 749,226 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.